Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): a Randomized, Double Blind, Multi-Center Phase 3 Trial

Next Previous
Search
Trial Profile

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): a Randomized, Double Blind, Multi-Center Phase 3 Trial

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegargiminase (Primary) ; Docetaxel; Gemcitabine
  • Indications Leiomyosarcoma; Uterine leiomyoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ARGSARC

    • Most Recent Events

    • 04 Dec 2023 According to a Polaris Pharmaceuticals media release, first patient has been dosed in this trial.
    • 27 Nov 2023 Status changed from not yet recruiting to recruiting.
    • 13 Jul 2023 Planned initiation date changed from 15 Jun 2023 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top